Latest Breaking News On - National reimbursement drug list - Page 6 : vimarsana.com

CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

SUZHOU, China, March 27, 2024 /PRNewswire/ CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research,

United statesUnited kingdomCity ofHong kongLes laboratoires servierJason yangNational medical products administrationEsmo gi congressChinese medical associationCstone pharmaceuticalsResearch pipeline leveraging multiple sources of innovationChinese society of clinical oncologyInternational financial reporting standardsClinical cancer research3sbio incBlueprint medicines corporation

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved.

United statesAscentage pharaPrnewswire ascentage pharmaAscentage pharmaDajun yangDrug administrationGlobal manufacturing centerNational reimbursement drug listNational comprehensive cancer networkAmerican society of clinical oncology annual meetingEuropean unionChina national medical products administrationAmerican society of hematologyModel productChina developed innovative drugsReimbursement drug list

Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Data readout from Phase 3 clinical trial in the People s Republic of China evaluating F351 for the treatment of CHB-associated liver fibrosis expected by early 2025 U.S. Phase 2a clinical trial.

United statesJapan generalSan diegoChan yingStephen jasperRodneyl nussbaumPreclinical development updatesNational reimbursement drug listAudit committeeClinical development updatesExchange commissionCatalyst biosciences incCompany board of directorsArthur andersenContinent pharmaceuticals co ltdGyre therapeutics inc

Gyre Therapeutics, Inc : Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Gyre Therapeutics, Inc : Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJapan generalChan yingSan diegoDennis riedlStephen jasperRodneyl nussbaumCatalyst biosciences incGyre therapeutics incGc biopharma corpPreclinical development updatesCompany board of directorsGyre pharmaceuticalsErnst youngAudit committeeNational reimbursement drug list

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesJasmine cuiChunhua luInnocare pharmaNational reimbursement drug listCare pharmaInvestigational new drug